INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 13, 2018 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | 94,048 |
| Dec 13, 2018 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 94,048 | -- | -- |
| Dec 13, 2017 |
Director, President & CSO
|
Director, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,438 | $21.92 | 786,786 |
| Dec 13, 2017 |
Director, President & CSO
|
Director, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,438 | -- | -- |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | $20.32 | 697,000 |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | -- | -- |
| Dec 16, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,921 | $52.03 | 501,921 |
| Dec 16, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,921 | -- | -- |
| Oct 30, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 182,818 | $11.64 | 682,818 |
| Oct 30, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 182,818 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.